| 摘要 |
<p>Pharmaceutical composition and methods of use of an amyloid-beta binding protein from serum and cerebral spinal fluid of Alzheimer's disease and normal aged patients with an estimated size of 350-400 kilodaltons, designated P400. P400 is decreased in serum derived from Alzheimer's disease patients in comparison to normal aged controls. P400 is more abundant than apolipoproteins and laminin in biological fluids and binds Amyloid-beta with a higher affinity.</p> |
